Kalaris Therapeutics, Inc. Common Stock
KLRSKalaris Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies for autoimmune and inflammatory diseases. The company leverages its proprietary platform to discover and advance treatments aimed at modulating the immune system to restore balance and improve patient outcomes.
Company News
Kalaris Therapeutics announced positive Phase 1a data for TH103, its investigational treatment for neovascular AMD. The expanded trial of 17 treatment-naive patients showed improvements in vision and retinal anatomy, with 29% requiring no additional anti-VEGF treatment during six-month follow-up. TH103 demonstrated 27-53 fold lower plasma levels ...
Kalaris Therapeutics announced it will present Phase 1a clinical data for TH103, a novel dual-targeting VEGF/HSPG biologic, at the American Society of Retina Specialists 2026 Annual Meeting on July 17, 2026. The company's Phase 1b/2 multiple ascending dose study for neovascular age-related macular degeneration is actively enrolling patients, with...
Kalaris Therapeutics secured a $50 million private placement with institutional investors to advance clinical development of TH103 for neovascular AMD, with funds expected to support operations through Q3 2027.
Kalaris Therapeutics reported Q2 2025 financial results, continuing enrollment in a Phase 1 trial for TH103, a novel anti-VEGF treatment for retinal diseases. The company has $88.4M in cash, expects initial clinical data in Q4 2025, and reported a net loss of $11.4 million for the quarter.
